These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22352796)

  • 1. A water-based mechanism of specificity and resistance for lapatinib with ErbB family kinases.
    Huang Y; Rizzo RC
    Biochemistry; 2012 Mar; 51(12):2390-406. PubMed ID: 22352796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
    Gilmer TM; Cable L; Alligood K; Rusnak D; Spehar G; Gallagher KT; Woldu E; Carter HL; Truesdale AT; Shewchuk L; Wood ER
    Cancer Res; 2008 Jan; 68(2):571-9. PubMed ID: 18199554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico design: extended molecular dynamic simulations of a new series of dually acting inhibitors against EGFR and HER2.
    Ahmed M; Sadek MM; Abouzid KA; Wang F
    J Mol Graph Model; 2013 Jul; 44():220-31. PubMed ID: 23911931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homology models of the mutated EGFR and their response towards quinazoline analogues.
    Kotra S; Madala KK; Jamil K
    J Mol Graph Model; 2008 Oct; 27(3):244-54. PubMed ID: 18585943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
    Tevaarwerk AJ; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atomistic insights into the lung cancer-associated L755P mutation in HER2 resistance to lapatinib: a molecular dynamics study.
    Yang B; Zhang H; Wang H
    J Mol Model; 2015 Feb; 21(2):24. PubMed ID: 25620423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR.
    Michalczyk A; Klüter S; Rode HB; Simard JR; Grütter C; Rabiller M; Rauh D
    Bioorg Med Chem; 2008 Apr; 16(7):3482-8. PubMed ID: 18316192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2.
    Bello M; Saldaña-Rivero L; Correa-Basurto J; García B; Sánchez-Espinosa VA
    Int J Biol Macromol; 2018 May; 111():569-586. PubMed ID: 29329808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations.
    Avizienyte E; Ward RA; Garner AP
    Biochem J; 2008 Oct; 415(2):197-206. PubMed ID: 18588508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.
    Kim JW; Kim HP; Im SA; Kang S; Hur HS; Yoon YK; Oh DY; Kim JH; Lee DS; Kim TY; Bang YJ
    Cancer Lett; 2008 Dec; 272(2):296-306. PubMed ID: 18774637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico identification of significant detrimental missense mutations of EGFR and their effect with 4-anilinoquinazoline-based drugs.
    Rajasekaran R; Sethumadhavan R
    Appl Biochem Biotechnol; 2010 Mar; 160(6):1723-33. PubMed ID: 19455431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding mechanism of kinase inhibitors to EGFR and T790M, L858R and L858R/T790M mutants through structural and energetic analysis.
    Bello M
    Int J Biol Macromol; 2018 Oct; 118(Pt B):1948-1962. PubMed ID: 30017980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Dynamics Analysis of Binding of Kinase Inhibitors to WT EGFR and the T790M Mutant.
    Park J; McDonald JJ; Petter RC; Houk KN
    J Chem Theory Comput; 2016 Apr; 12(4):2066-78. PubMed ID: 27010480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases.
    Singh J; Dobrusin EM; Fry DW; Haske T; Whitty A; McNamara DJ
    J Med Chem; 1997 Mar; 40(7):1130-5. PubMed ID: 9089334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.
    Trowe T; Boukouvala S; Calkins K; Cutler RE; Fong R; Funke R; Gendreau SB; Kim YD; Miller N; Woolfrey JR; Vysotskaia V; Yang JP; Gerritsen ME; Matthews DJ; Lamb P; Heuer TS
    Clin Cancer Res; 2008 Apr; 14(8):2465-75. PubMed ID: 18413839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase.
    Ban HS; Usui T; Nabeyama W; Morita H; Fukuzawa K; Nakamura H
    Org Biomol Chem; 2009 Nov; 7(21):4415-27. PubMed ID: 19830290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase.
    Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM
    Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel oxazolo[4,5-g]quinazolin-2(1H)-ones: dual inhibitors of EGFR and Src protein tyrosine kinases.
    Lin J; Shen W; Xue J; Sun J; Zhang X; Zhang C
    Eur J Med Chem; 2012 Sep; 55():39-48. PubMed ID: 22818848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.
    Yu Z; Boggon TJ; Kobayashi S; Jin C; Ma PC; Dowlati A; Kern JA; Tenen DG; Halmos B
    Cancer Res; 2007 Nov; 67(21):10417-27. PubMed ID: 17974985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.